Pharmacoeconomic evaluation of Donafenib in the treatment of advanced hepatocellular carcinoma
Objective To assess the drug economy of donafenib,a domestically developed innovative treatment for advanced hepatocellular carcinoma(HCC),from the perspective of China's healthcare system,aiming to provide a reference for the rational use of donafenib and the efficient allocation of healthcare resources.Methods Treeage Pro 2011 was utilized to construct a Markov model to simulate disease progression in different states.Based on survival data from the ZGDH3 clinical trial,the transfer probability is cal-culated,and the cost and utility values under different states are obtained.From the perspective of China's health system,the cost-ef-fectiveness of donafenib first-line treatment for hepatocellular carcinoma is evaluated.Sensitivity analysis is used to explore the impact of parameters on the results with the primary indicators being total cost,quality adjusted life years(QALYs),and incremental cost u-tility ratio(ICUR).Results After a 10-year simulation,Donafenib produced 1.28 QALYs,with a total cost of 193,475.71 yuan.Compared with Sorafenib,the incremental QALYs is 0.23,the incremental cost is 55,910.08 yuan,and the ICUR is 241,229.83.Uni-variate sensitivity analysis indicated that the drug price of donafenib and the utility values associated with disease progression states sig-nificantly influenced the outcomes.The probability sensitivity analysis shows that when the willingness-to-pay(WTP)threshold is 257,094 yuan,the probability of Donafenib having economic advantages is 56.15%.Conclusion From the perspective of China's health system,donafenib demonstrates greater economic advantages in the first-line treatment of advanced HCC patients compared to sorafenib,especially when the WTP threshold is set at 257,094 CNY.In addition,lowering the price of donafenib can benefit more pa-tients with HCC.
NETL
NSTL
万方数据
